Ironwood Pharmaceuticals
IRWD
248 hedge funds and large institutions have $1.56B invested in Ironwood Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 78 increasing their positions, 101 reducing their positions, and 40 closing their positions.
21% more call options, than puts
Call options by funds: $3.54M | Put options by funds: $2.93M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 40
2% less funds holding
Funds holding: 252 → 248 (-4)
4.59% less ownership
Funds ownership: 106.92% → 102.33% (-4.6%)
12% less capital invested
Capital invested by funds: $1.77B → $1.56B (-$204M)
23% less repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 101
Top Buyers
| 1 |
AC
Armistice Capital
New York
|
+$33.9M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$23.3M |
| 3 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$18.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.9M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$13.2M |
Top Sellers
| 1 |
Man Group
London,
United Kingdom
|
-$29.2M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$26.2M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$16.3M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$14.6M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$12.7M |
IRWD Hedge Fund Activity: Q3 2023 in Review
248 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2023, worth a combined $1.56B — down 12% from $1.77B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of IRWD and 38 opened new positions — a net loss of 2 holders — while 101 trimmed existing stakes and 78 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $33.9M. The largest seller was Man Group, exiting entirely with an estimated $29.2M sold.
- 248 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2023, down from 252 in Q2 2023.
- Funds reported $1.56B of Ironwood Pharmaceuticals stock for Q3 2023, down 12% quarter-over-quarter.
- 38 funds opened new Ironwood Pharmaceuticals positions in Q3 2023 and 40 closed out, a net change of -2 holders.
- The largest Ironwood Pharmaceuticals buyer in Q3 2023 was Armistice Capital, an estimated $33.9M added.
- The largest Ironwood Pharmaceuticals seller in Q3 2023 was Man Group, an estimated $29.2M sold.
Based on aggregated 13F filings for Q3 2023.